tw0122
6 días hace
GOVX to the bird flu rescue .. Bird Flu in Cats New Jersey
Two domestic cats in New Jersey have tested positive for the highly pathogenic avian influenza (H5N1) in Hunterdon County. One feral cat developed severe disease, including neurologic signs, and was euthanized. Another indoor-outdoor cat also tested positive, and tests on other cats on the property are pending.Additional Details:Symptoms in Cats: Clinical signs of bird flu in cats can include respiratory signs (discharge from the eyes and mouth, sneezing, coughing, difficulty breathing) and neurologic signs.Transmission: Cats can contract the virus through exposure to infected birds or other animals, contaminated environments, or by consuming raw/undercooked meat or milk from infected sources.Prevention: Pet owners are advised to avoid feeding cats raw milk or meat, avoid contact with sick or dead birds and wildlife, and thoroughly wash hands and change clothes after handling sick animals.Human Risk: While the risk of H5N1 infection to the general population remains low, close contact with infected animals can pose a risk. No human cases have been reported in New Jersey.Reporting: New Jersey residents should contact their veterinarian if they have concerns about their pets. Suspect feline cases should be reported to the New Jersey Department of Health at 609-826-4872 or zoonoticrn@doh.nj.gov.
tw0122
6 meses hace
Mpox has spread to at least 14 African countries, including Morocco, which has confirmed its first case in the current outbreak. (Source: BBC Africa)
The Democratic Republic of Congo (DRC) is the epicenter of the outbreak, with over 20,000 cases reported and more than 500 deaths. (Source: WHO)
Neighboring countries, such as Burundi, Kenya, Rwanda, and Uganda, have also reported cases. (Source: WHO)
Vaccination Efforts
The World Health Organization (WHO) recommends use of MVA-BN or LC16 vaccines, or the ACAM2000 vaccine when others are not available. (Source: WHO)
Only people at risk of exposure to mpox should be considered for vaccination, according to WHO. (Source: WHO)
Transmission and Prevention
Mpox is primarily spread through close person-to-person contact with someone who is infected, including through sex. (Source: Nature)
Cleaning and disinfecting surfaces or objects and washing hands after touching contaminated surfaces or objects can help prevent transmission. (Source: WHO)
Avoiding unprotected contact with wild animals, especially those that are sick or dead, and cooking food thoroughly can reduce the risk of getting mpox from animals. (Source: WHO)
Public Health Emergency
The WHO declared the mpox outbreak a Public Health Emergency of International Concern (PHEIC) on August 19, 2024, citing the rapid spread of a new, more transmissible strain of the virus. (Source: WHO)
Research and Development
Scientists are racing to answer questions about the outbreak, including whether vaccines will curb the spread and how the virus is transmitted. (Source: Nature)
tw0122
6 meses hace
price of $5.125 per share for expected gross proceeds of $5 million.
4:39 AM EDT, 08/29/2024 (MT Newswires) -- GeoVax Labs (GOVX) said late Wednesday it has agreed to sell 975,610 common shares in a registered direct offering to an institutional investor at a price of $5.125 per share for expected gross proceeds of $5 million.
The company will also issue warrants to purchase up to 975,610 common shares to the investor in a concurrent private placement, it said. The warrants will be exercisable at a price of $5 per share.
Net proceeds will be used for working capital and general corporate purposes, the company said.
The offering is expected to close around Friday, sub
tw0122
6 meses hace
Covid flue season blooming still holding a few here but inclined to add some more ..
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world’s most threatening infectious diseases and therapies for solid tumor cancers. The company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. The Company has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.
tw0122
6 meses hace
sale of 1,700,000 shares of the Company’s common stock (or common stock equivalents) at a price of $5.00 per share in a registered direct offering priced above-the-market under Nasdaq rules.
In addition, in a concurrent private placement, the Company will issue to the investor warrants to purchase up to 1,700,000 shares of common stock. The warrants have an exercise price of $5.00 per share, will be exercisable immediately following the date of issuance and will have a term of five years from the date of issuance.